Beta 2 adrenergic receptor agonists as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) - npj Metabolic Health and Disease

Likely AI

dx.doi.orgby …March 25, 2026Submitted May 9, 2026

IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are closely associated with type 2 diabetes (T2D). There are an...

The Verdict

ClassificationLikely AI

ConfidenceMedium confidence

Analyzedtext

Community Verdict

Be the first to vote on this assessment.

Embed Badge

Add this badge to your site to show the AI classification for this content.

[![Real Press](https://real.press/api/badge/b08a46d1-4d13-474a-8efb-92de312aaa89)](https://real.press/content/b08a46d1-4d13-474a-8efb-92de312aaa89)